Findings of Biopsy-Proven Chronicity and End-Stage Renal Failure Associated with Oral Sodium Phosphate Solution

Cakar, Mustafa; Kanbay, Mehmet; Sarlak, Hakan; Akhan, Muharrem; Gök, Mahmut; Ünal, Hilmi Umut; Demirbaş, Şeref; Yılmaz, Mahmut İlker

doi:10.3109/0886022x.2011.654145

Cited by 8 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…()18/FIleus 11,600 (2 × 5,800 within 12 h)Haemodialysis remission Baseline: 0.41 Onset: 0.87–1.08 Follow‐up: 0.60 3 Cakar et al. ()65/MHypertension 11,600 (2 × 5,800 within 12 h)CKD. Patient started haemodialysis treatment Baseline: 1.14 Onset: 1.82 Follow‐up: 3.14 Kidney biopsy showed mild focal tubulointerstitial inflammation, tubular atrophy, sclerosis4Fine and Patterson ()84/FHypertension, mild cardiac insufficiency.…”

Section: Appendix P – Case Series and Case Reports After Acute Administrationmentioning

confidence: 99%

Re‐evaluation of phosphoric acid–phosphates – di‐, tri‐ and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use

Flavourings¹,

Younes²,

Aquilina³

et al. 2019

EFS2

View full text Add to dashboard Cite

The Panel on Food Additives and Flavourings added to Food (FAF) provided a scientific opinion re-evaluating the safety of phosphates (E 338-341, E 343, E 450-452) as food additives. The Panel considered that adequate exposure and toxicity data were available. Phosphates are authorised food additives in the EU in accordance with Annex II and III to Regulation (EC) No 1333/2008. Exposure to phosphates from the whole diet was estimated using mainly analytical data. The values ranged from 251 mg P/person per day in infants to 1,625 mg P/person per day for adults, and the high exposure (95th percentile) from 331 mg P/person per day in infants to 2,728 mg P/person per day for adults. Phosphate is essential for all living organisms, is absorbed at 80-90% as free orthophosphate excreted via the kidney. The Panel considered phosphates to be of low acute oral toxicity and there is no concern with respect to genotoxicity and carcinogenicity. No effects were reported in developmental toxicity studies. The Panel derived a group acceptable daily intake (ADI) for phosphates expressed as phosphorus of 40 mg/kg body weight (bw) per day and concluded that this ADI is protective for the human population. The Panel noted that in the estimated exposure scenario based on analytical data exposure estimates exceeded the proposed ADI for infants, toddlers and other children at the mean level, and for infants, toddlers, children and adolescents at the 95th percentile. The Panel also noted that phosphates exposure by food supplements exceeds the proposed ADI. The Panel concluded that the available data did not give rise to safety concerns in infants below 16 weeks of age consuming formula and food for medical purposes.

show abstract

Section: Appendix P – Case Series and Case Reports After Acute Administrationmentioning

confidence: 99%

Re‐evaluation of phosphoric acid–phosphates – di‐, tri‐ and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use

Flavourings¹,

Younes²,

Aquilina³

et al. 2019

EFS2

View full text Add to dashboard Cite

show abstract

“…This improves the consistency of the final product, upholds the weight and preserves the sensory characteristics (Goncalves, Rech, Rodrigues, & Pucci, 2008;Goncalves and Ribeiro 2008;Campden, 2012). Generally, polyphosphates are acknowledged as nontoxic, but some authors have observed that a high dietary introduction of these additives can cause hypocalcemia, renal injury with calcium phosphate accumulation in the kidneys (Weiner et al, 2001;Cakar et al, 2012). Impairment of the calcium-phosphorus ratio leads to certain hormonal disorders, while excess phosphates species interferes with calcium absorption in the gut, which results in the release of calcium from bones (Weiner et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Detection of polyphosphates in seafood and its relevance toward food safety

et al. 2020

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…The incidence of clinically important adverse renal events after OSP use cannot be exactly quantified in the general or at-risk populations, since the majority of significant problems are drawn from relatively few (» 20) isolated case reports or case series of biopsy-confirmed APhN [7,50,52,67,80,[87][88][89][90]95,109,[111][112][113][114][115][116][117][118]121,122,124,128,129].…”

Section: Studies Evaluating the Risk Of Renal Impairment After Osp Usementioning

confidence: 99%

Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others

Hoffmanová¹,

Kraml²,

Andĕl³

2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Because of safety concerns, sodium phosphate purgatives are not recommended for routine bowel cleansing. Despite some serious and even fatal adverse events associated with these drugs when used with at-risk patients, available data suggest that administration of sodium phosphate purgatives is relatively safe in nonrisk individuals(i.e., in adequately hydrated, otherwise healthy adults, younger than 55 years with evidence of normal renal function).

show abstract

Findings of Biopsy-Proven Chronicity and End-Stage Renal Failure Associated with Oral Sodium Phosphate Solution

Cited by 8 publications

References 8 publications

Re‐evaluation of phosphoric acid–phosphates – di‐, tri‐ and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use

Re‐evaluation of phosphoric acid–phosphates – di‐, tri‐ and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use

Detection of polyphosphates in seafood and its relevance toward food safety

Renal risk associated with sodium phosphate medication: safe in healthy individuals, potentially dangerous in others

Contact Info

Product

Resources

About